3月9日，由上海市生物医药产业发展领导小组办公室作为指导单位，赛默飞世尔科技、蒲公英Ouryao共同主办的首届中国疫苗创新与未来发展峰会在上海文华东方酒店举行。会议云集了行业领域内的专家，以“促疫苗发展，创产业未来”为主题，聚焦疫苗行业生态、政策趋势、法规解析、产业动向、创新策略、前沿技术六大板块，旨在积极推进中国疫苗创新及未来发展。公司CEO吴克博士受邀参加，并就“疫苗接力赛：如何打造疫苗稳定供应链”为主题做了演讲。
On March 9, the first China Vaccine Innovation and Future Development Summit, with the Shanghai Biomedical Industry Development Leading Group Office as the guiding unit, and co-sponsored by Thermo Fisher and Ouryao, was held at the Mandarin Oriental Hotel in Shanghai.
The meeting gathered experts from the industry, with the theme of "promoting the development of vaccines and creating the future of the industry", and focused on the six sectors including the vaccine industry ecology, policy trends, regulatory analysis, industry trends, innovation strategies, and cutting-edge technology, aiming to promote the innovation of China's vaccines.
Dr. Wu Ke, CEO of the company, was invited to attend and gave a speech on the theme of "Vaccine Relay Race: How to Build a Stable Supply Chain for Vaccines".
吴克博士在主题演讲中围绕“供应链管理与疫苗产业、冷链运输与新剂型疫苗开发、疫苗供给端与需求端解决策略”等方面做了分享。
In his keynote speech, Dr. Wu shared about "supply chain management and vaccine industry, cold chain transportation and new formulation vaccine development, vaccine supply and demand side solutions" and other aspects.
目前，博沃生物正积极与亚洲、欧洲和拉美地区的政府机构及制药企业洽谈合作事宜，以促进新型疫苗的推广和成果的全球化。未来，博沃将在兼顾国内市场的同时，积极开拓国外市场，与国际组织和各国政府开展深度合作，参与疫苗全球采购，为全球、特别是发展中国家提供具有高性比价的疫苗产品。
At present, BravoBio is negotiating cooperation with government agencies and pharmaceutical enterprises in Asia, Europe and Latin America to push forward the promotion of new vaccines and the globalization of results. In the future, while taking into account the domestic market, BravoBio will actively explore foreign markets, carry out in-depth cooperation with international organizations and governments, participate in the global procurement of vaccines, and provide vaccine products with high competitive price for the world, especially for developing countries.
关于博沃生物
上海博沃生物科技有限公司 2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a "state level high-tech enterprise" and a council member of China Association of Vaccines (CAV). It was awarded as "China Rising Star" by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people's lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注博沃生物
长按二维码 关注我们
公司官网｜www.bravobio.com